Cargando…

Development of Recombinant Immunotoxins for Hairy Cell Leukemia

Hairy cell leukemia (HCL) is an indolent B-cell malignancy with excellent initial response to purine analogs pentostatin or cladribine, but patients are rarely, if ever, cured. Younger patients will usually need repeat chemotherapy which has declining benefits and increasing toxicities with each cou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kreitman, Robert J., Pastan, Ira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464581/ https://www.ncbi.nlm.nih.gov/pubmed/32756468 http://dx.doi.org/10.3390/biom10081140

Ejemplares similares

Immunotoxins: From Design to Clinical Application
por: Kreitman, Robert J., et al.
Publicado: (2021)

Effect of Antigen Shedding on Targeted Delivery of Immunotoxins in Solid Tumors from a Mathematical Model
por: Pak, Youngshang, et al.
Publicado: (2014)

Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues
por: Kreitman, Robert J., et al.
Publicado: (2022)

Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy
por: Dieffenbach, Michael, et al.
Publicado: (2020)

Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity
por: Vallera, Daniel A., et al.
Publicado: (2018)

Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results
por: Mason-Osann, Emily, et al.
Publicado: (2015)

Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs
por: Berger, Edward A., et al.
Publicado: (2010)

Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient’s Bedside to Evaluation in Preclinical Models
por: Leshem, Yasmin, et al.
Publicado: (2019)

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
por: Mazor, Ronit, et al.
Publicado: (2016)

Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation
por: Mazor, Ronit, et al.
Publicado: (2020)

Targeting malignant B cells with an immunotoxin against ROR1
por: Baskar, Sivasubramanian, et al.
Publicado: (2012)

Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox
por: Robak, Tadeusz, et al.
Publicado: (2021)

Efficiency of Immunotoxin Cytotoxicity Is Modulated by the Intracellular Itinerary
por: Tortorella, Lori L., et al.
Publicado: (2012)

Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures
por: Liu, Wenlong, et al.
Publicado: (2022)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
por: Kreitman, Robert J., et al.
Publicado: (2018)

Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies
por: Müller, Fabian, et al.
Publicado: (2017)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery
por: Bao, Xuhui, et al.
Publicado: (2016)

Clinical targeting recombinant immunotoxins for cancer therapy
por: Li, Meng, et al.
Publicado: (2017)

Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P
por: Mattoo, Abid R., et al.
Publicado: (2013)

Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway
por: Liu, Xiu-Fen, et al.
Publicado: (2017)

Recombinant immunotoxins development for HER2-based targeted cancer therapies
por: Mahmoudi, Reza, et al.
Publicado: (2021)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial
por: Kreitman, Robert J., et al.
Publicado: (2021)

Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
por: Wang, Chunguang, et al.
Publicado: (2016)

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
por: Bera, T K, et al.
Publicado: (2018)

Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A
por: Kaplan, Gilad, et al.
Publicado: (2016)

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
por: Grever, Michael, et al.
Publicado: (2021)

Genomics of Hairy Cell Leukemia
por: Tiacci, Enrico, et al.
Publicado: (2017)

BRAF Mutation in Hairy Cell Leukemia
por: Ahmadzadeh, Ahmad, et al.
Publicado: (2014)

Hairy cell leukemia – immunotargets and therapies
por: Basheer, Faisal, et al.
Publicado: (2014)

The Biology of Classic Hairy Cell Leukemia
por: Bohn, Jan-Paul, et al.
Publicado: (2021)

Expression of the muscle-associated gene MYF6 in hairy cell leukemia
por: Arons, Evgeny, et al.
Publicado: (2020)

Hosts for Hostile Protein Production: The Challenge of Recombinant Immunotoxin Expression
por: Zuppone, Stefania, et al.
Publicado: (2019)

Skin changes in hairy cell leukemia
por: Robak, Ewa, et al.
Publicado: (2020)

Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
por: Leshem, Jasmin, et al.
Publicado: (2015)

SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors
por: Leshem, Yasmin, et al.
Publicado: (2018)

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
por: Chihara, Dai, et al.
Publicado: (2022)

Development of a distributed international patient data registry for hairy cell leukemia
por: Andritsos, Leslie A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a3fhp7ithpcjqe8ei09kdhgv90